JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin reiterated a Market Outperform rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $17 price target.
June 12, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities reiterated a Market Outperform rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $17 price target.
The news of JMP Securities reiterating a Market Outperform rating and maintaining a $17 price target for Sutro Biopharma is positive for the company's stock. This shows that the analyst has confidence in the company's performance and potential growth, which could lead to an increase in demand for the stock and a potential rise in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100